Table 1 Patient characteristics

From: MCSP+ metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization

Characteristic

Number of patients

Percentage

Median

Range

Interquartile range

Patients

435

    

Gender

 Female

192

44.1

   

 Male

243

55.9

   

Age (years)

  

56

15–85

 

Breslow’s thickness (mm)

  

2

0.2–15.0

1–3

Ulceration

 No

278

63.9

   

 Yes

153

35.2

   

 Not specified

4

0.9

   

Localization

 Extremities

252

57.9

   

 Trunk or head

183

42.1

   

Nodal status histopathology

 Negative

342

78.6

   

 Positive

93

21.4

   

Clinical stage

 IA

49

11.3

   

 IB

168

38.6

   

 II

1

0.2

   

 IIA

73

16.8

   

 IIB

40

9.2

   

 IIC

12

2.8

   

 III

4

0.9

   

 IIIA

32

7.4

   

 IIIB

38

8.7

   

 IIIC

17

3.9

   

 IIID

1

0.2

   

DCCDa (MCSP)

  

5

0–400,000

1–12

DCCDb (gp100)

  

0

0–500,000

0–1

Survival

 Deceased

98

22.5

   

 Alive

337

77.5

   

Adjuvant therapy

 Yesc

54

12.4

   

 No/not specified

381

87.6

   
  1. aDCCD in the SLN: number of MCSP+ cells per million isolated cells; if more than one node per patient was positive, the node with the highest cancer cell density was taken.
  2. bDCCD in the SLN: number of gp100+ cells per million isolated cells; if more than one node per patient was positive, the node with the highest cancer cell density was taken.
  3. cOf the 54 patients, three received pembrolizumab, 47 received IFNG and four received unspecified therapy.
Back to article page